Two clinical trials looking at the use of radiotherapy and immunotherapy for metastatic renal cell carcinoma (RCC) were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. First was the Phase II NIVES trial. In this trial, advanced kidney cancer patients who had been treated with targeted […]
In this video interview, Dr Vitaly Margulis, from the University of Texas Southwestern Medical Center in Dallas, outlines the advantages of stereotactic body radiation therapy (SBRT) and talks about the forthcoming RADVAX clinical trial in the USA, which combines radiotherapy and immunotherapy. Oncologists are often taught that renal cell carcinoma (RCC) is resistant to radiotherapy. […]
This paper reviews the use of stereotactic body radiotherapy (SBRT) for the treatment of renal cell carcinoma (RCC), and was presented at the Society of Urologic Oncology (SUO) in Washington last week. In conclusion: RCC is radiosensitive and SBRT can be used to stabilise or manage the symptoms of primary tumours SBRT may be useful […]
Two recent studies have looked at the effect of stereotactic body radiotherapy (SBRT) in combination with tyrosine kinase inhibitors or immune checkpoint inhibitors on renal cell carcinoma (RCC) metastases and survival. In the first study, a total of 17 patients with stable metastatic RCC were assessed. The effect of SBRT on the target metastasis was […]
Two small studies looked at the addition of a type of radiotherapy treatment, called stereotactic body radiotherapy (SBRT), to treatment with a tyrosine kinase inhibitor (TKI), such as sunitinib or pazopanib, or a checkpoint inhibitor, such as nivolumab for patients with metastatic renal cell carcinoma (RCC). In the first study, 56 patients with metastatic RCC […]
This paper reviews the use of stereotactic ablative radiotherapy (SABR) (also called stereotactic body radiotherapy, SBRT) for treating primary renal cell carcinoma (RCC) that cannot be removed with surgery. SABR is a treatment that automatically targets high doses of radiotherapy to the tumour with high precision. SABR is very accurate, and thereby maximises the cell-killing […]
A recent study published in The Journal of Urology this month suggests that stereotactic body radiotherapy (SBRT) may be a safe and effective therapeutic option that could control the growth of localised, small numbers of metastases (oligometastatic) in people with advanced renal cell carcinoma (RCC). Fifty-eight RCC patients, who had undergone surgery and had a maximum […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
